Bio Industry

Human genetic variation-based targeting increases the probability of success, but mostly for rare diseases (small patient populations) → commercial success is difficult. Age-related diseases represent the largest market (TAM), but genetic targets and existing approaches barely work. Drug development mimicking interventions with proven multi-pathway effects, like exercise, is limited due to complexity, while targeting "obvious targets" such as amyloid, complement proteins, etc. has shown no clinical efficacy.